Valérie Taly's Biography

Valérie Taly, CNRS Research Director, Professor and Group leader Translational Research and Microfluidics, Université Paris Cité

V. Taly is a CNRS research director and group leader of the Translational Research And Microfluidics team within the clinical oncology research unit MEPPOT (personalized medicine pharmacogenomics and therapeutic optimization) in the Cordeliers Research Center (university Paris Cité). Her team performs interdisciplinary researches aiming at developing and validating microfluidic tools for cancer research in close collaboration with clinicians and researchers in oncology and toxicology. Since 2008, she developed droplet-based digital procedures for Cancer diagnosis. Recently, her research has been dedicated to the clinical validation of droplet-based microfluidics for the non-invasive detection of Cancer biomarkers, the highlighting of new Cancer Biomarkers and the development of original tools and procedures for their detection with applications in personalized medicine, cancer recurrence detection and cancer diagnostics. She is co-founder of EMULSEO (2018) and METHYS DX (2021) start up companies.

Microfluidics For Cancer Research

Tuesday, 21 June 2022 at 09:00

Add to Calendar ▼2022-06-21 09:00:002022-06-21 10:00:00Europe/LondonMicrofluidics For Cancer ResearchLab-on-a-Chip and Microfluidics Europe 2022 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com

Droplet-based microfluidics has led to the development of highly powerful tools with great potential in High-Throughput Screening where individual assays are compartmentalized within aqueous droplets acting as independent microreactors. Thanks to the combination of a decrease of assay volume and an increase of throughput, this technology goes beyond the capacities of conventional screening systems. Added to the flexibility and versatility of platform designs, such progresses in the manipulation of sub-nanoliter droplets has allowed to dramatically increase experimental level of control and precision. This technology has been key to recent developments in cancer research. These recent developments will be central to this presentation. In particular, we will show how by combining microfluidic systems and clinical advances in molecular diagnostic we have developed an original method to perform millions of single molecule PCR in parallel to detect and quantify a minority of target sequences in complex mixture of DNA with a sensitivity unreachable by conventional procedures. To demonstrate the pertinence of our procedures to overcome clinical oncology challenges, the results of clinical studies will be presented.

Add to Calendar ▼2022-06-21 00:00:002022-06-22 00:00:00Europe/LondonLab-on-a-Chip and Microfluidics Europe 2022Lab-on-a-Chip and Microfluidics Europe 2022 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com

Corporate Sponsors